https://www.nasdaq.com/press-release/biocept-to-present-at-the-h.c.-wainwright-bioconnect-virtual-conference-on-january-10
https://www.nasdaq.com/press-release/biocepts-cnside-cerebrospinal-fluid-assay-identifies-actionable-her2-mutations-in
https://www.nasdaq.com/press-release/quest-diagnostics-now-offers-biocepts-liquid-biopsy-test-for-lung-cancer-expanding
https://www.nasdaq.com/press-release/clinical-validation-is-completed-for-new-covid-19-assay-designed-by-aegea
https://www.nasdaq.com/press-release/biocept-launches-combined-covid-19-and-influenza-test-to-provide-answers-during-peak
https://www.nasdaq.com/press-release/correcting-and-replacing-biocepts-cnside-cerebrospinal-fluid-assay-aids-in-monitoring
https://www.nasdaq.com/press-release/biocept-reports-third-quarter-2021-financial-results-2021-11-15
https://www.nasdaq.com/press-release/study-shows-biocepts-switch-blocker-technology-enhances-performance-of-conventional
https://www.nasdaq.com/press-release/biocept-to-report-third-quarter-2021-financial-results-and-host-investor-conference
https://www.nasdaq.com/press-release/biocept-to-present-at-the-ld-micro-main-event-on-october-13-2021-10-06
https://www.nasdaq.com/press-release/biocept-implements-covid-19-testing-program-at-select-california-community-colleges
https://www.nasdaq.com/press-release/biocept-invites-you-to-join-us-at-the-benzinga-healthcare-small-cap-conference-2021
https://www.nasdaq.com/press-release/biocept-to-present-data-at-ras-targeted-drug-development-summit-showing-ability-of
https://www.nasdaq.com/press-release/biocept-to-present-at-four-virtual-investor-conferences-in-september-2021-09-07
https://www.nasdaq.com/press-release/biocept-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-08-31
https://www.nasdaq.com/press-release/biocepts-cnside-assay-identifies-tumor-cells-and-actionable-treatment-biomarkers-from
https://www.nasdaq.com/press-release/biocept-reports-second-quarter-2021-financial-results-2021-08-16
https://www.nasdaq.com/press-release/biocept-to-report-second-quarter-2021-financial-results-and-host-investor-conference
https://www.nasdaq.com/press-release/biocept-names-david-karlander-as-senior-vice-president-of-commercial-operations-2021
https://www.nasdaq.com/press-release/medicare-issues-local-coverage-determination-for-biocepts-target-selectortm-breast
https://www.nasdaq.com/press-release/biocept-welcomes-linda-rubinstein-and-antonino-morales-to-board-of-directors-names
https://www.nasdaq.com/press-release/biocept-to-participate-in-two-july-investment-conferences-2021-07-19
https://www.nasdaq.com/press-release/biocept-receives-south-korean-patent-for-primer-switch-platform-used-to-identify-rare
https://www.nasdaq.com/press-release/biocept-joins-the-russell-microcapr-index-2021-06-28
https://www.nasdaq.com/press-release/biocept-to-collaborate-with-quest-diagnostics-to-provide-advanced-ngs-based-liquid
https://www.nasdaq.com/press-release/biocept-receives-more-than-420000-samples-during-first-year-of-offering-covid-19
https://www.nasdaq.com/press-release/biocept-and-cleared4-collaborate-to-develop-new-service-for-managing-covid-19-testing
https://www.nasdaq.com/press-release/biocept-to-present-at-the-ld-micro-virtual-invitational-xi-conference-on-june-9-2021
https://www.nasdaq.com/press-release/biocept-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-06-02
https://www.nasdaq.com/press-release/biocept-reports-first-quarter-2021-financial-results-2021-05-12
https://www.nasdaq.com/press-release/biocept-to-report-first-quarter-2021-financial-results-and-host-investor-conference
https://www.nasdaq.com/press-release/biocept-to-supply-covid-19-testing-through-partnership-with-the-foundation-for
https://www.nasdaq.com/press-release/biocept-announces-full-commercial-launch-of-cnsidetm-cerebrospinal-fluid-assay-to
https://www.nasdaq.com/press-release/biocept-provides-update-on-covid-19-testing-with-more-than-350000-samples-received-to
https://www.nasdaq.com/press-release/biocept-to-host-key-opinion-leader-webinar-to-discuss-its-csf-assay-for-the-diagnosis
https://www.nasdaq.com/press-release/biocept-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-04-01
https://www.nasdaq.com/press-release/biocept-to-host-key-opinion-leader-webinar-on-april-8-to-discuss-its-csf-assay-for
https://www.nasdaq.com/press-release/biocept-reports-2020-fourth-quarter-and-full-year-financial-results-2021-03-29
https://www.nasdaq.com/press-release/biocept-to-report-2020-fourth-quarter-and-full-year-financial-results-and-host
https://www.nasdaq.com/press-release/biocept-to-participate-in-three-virtual-investment-conferences-in-march-2021-03-09
https://www.nasdaq.com/press-release/biocept-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-03-03
https://www.nasdaq.com/press-release/aegea-biotechnologies-announces-supply-agreement-with-biocept-for-new-covid-19-test
https://www.nasdaq.com/press-release/aegea-biotechnologies-announces-supply-agreement-with-biocept-for-new-covid-19-test-0
https://www.nasdaq.com/press-release/biocept-and-protean-biodiagnostics-establish-research-collaboration-to-demonstrate
https://www.nasdaq.com/press-release/study-shows-biocepts-target-selectortm-detects-mutations-in-quantity-not-sufficient
https://www.nasdaq.com/press-release/biocept-provides-update-on-covid-19-testing-with-more-than-250000-samples-received
https://www.nasdaq.com/press-release/biocept-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-02-02
https://www.nasdaq.com/press-release/biocept-issues-letter-to-stockholders-2021-01-12
https://www.nasdaq.com/press-release/biocept-to-present-at-h.c.-wainwright-virtual-bioconnect-conference-2021-01-04
https://www.nasdaq.com/press-release/biocept-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-12-31
https://www.nasdaq.com/press-release/biocept-enters-into-laboratory-services-agreements-with-two-southern-california
https://www.nasdaq.com/press-release/biocept-provides-business-update-2020-12-14
https://www.nasdaq.com/press-release/biocepts-target-selectortm-liquid-biopsy-demonstrated-high-accuracy-when-used-for
https://www.nasdaq.com/press-release/while-the-u.s.-faces-insufficient-covid-19-testing-volume-eir-healthcare-launches
https://www.nasdaq.com/press-release/study-shows-biocepts-assays-are-viable-and-sensitive-for-detecting-tumor-cells-and
https://www.nasdaq.com/press-release/results-from-study-using-biocepts-target-selectortm-testing-to-monitor-breast-cancer
https://www.nasdaq.com/press-release/biocept-reports-third-quarter-2020-financial-results-2020-11-12
https://www.nasdaq.com/press-release/biocept-provides-update-on-covid-19-testing-with-more-than-100000-samples-received
https://www.nasdaq.com/press-release/biocept-receives-hong-kong-patent-covering-the-enhanced-detection-of-rare-cells
https://www.nasdaq.com/press-release/biocept-awarded-broad-japanese-patent-for-the-use-of-binding-entities-in-combination
https://www.nasdaq.com/press-release/biocept-to-release-third-quarter-2020-financial-results-and-host-investor-conference
https://www.nasdaq.com/press-release/biocept-provides-update-on-covid-19-testing-with-more-than-80000-samples-received
https://www.nasdaq.com/press-release/biocept-appoints-samuel-d.-riccitelli-to-its-board-of-directors-2020-10-21
https://www.nasdaq.com/press-release/biocept-provides-update-on-covid-19-testing-with-more-than-50000-specimens-received
https://www.nasdaq.com/press-release/study-shows-biocepts-target-selectortm-may-provide-a-more-robust-method-for-detecting
https://www.nasdaq.com/press-release/biocept-to-present-study-results-from-target-selectortm-testing-in-the-cerebrospinal
https://www.nasdaq.com/press-release/aegea-biotechnologies-inc.-announces-the-award-of-japanese-patent-for-primer-switch
https://www.nasdaq.com/press-release/biocept-announces-the-award-of-japanese-patent-for-primer-switch-mutation-detection
https://www.nasdaq.com/press-release/biocept-announces-that-highmark-has-made-a-positive-coverage-determination-on-target
https://www.nasdaq.com/press-release/biocept-provides-covid-19-testing-update-with-more-than-35000-specimens-received-2020
https://www.nasdaq.com/press-release/aegea-biotechnologies-inc.-advances-to-semi-finals-of-the-%245m-xprize-rapid-covid
https://www.nasdaq.com/press-release/biocept-to-present-at-the-h.c.-wainwright-global-investment-virtual-conference-on
https://www.nasdaq.com/press-release/biocept-executes-in-network-provider-agreement-with-health-net-federal-services
https://www.nasdaq.com/press-release/biocept-announces-one-for-ten-reverse-stock-split-2020-09-04
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/biocept-provides-covid-19-testing-update-with-more-than-21000-covid-19-specimens
https://www.nasdaq.com/press-release/biocept-to-present-at-the-ld-micro-500-virtual-conference-2020-08-27
https://www.nasdaq.com/press-release/biocept-names-michael-dugan-m.d.-chief-medical-officer-and-medical-director-2020-08
https://www.nasdaq.com/press-release/biocept-to-present-at-the-proactive-one2one-virtual-investor-forum-on-august-25-2020
https://www.nasdaq.com/press-release/biocept-expands-agreement-with-multiplan-to-include-covid-19-testing-2020-08-19
https://www.nasdaq.com/press-release/aegea-biotechnologies-inc.-announces-the-issuance-of-u.s.-patent-for-primer-switch
https://www.nasdaq.com/press-release/biocept-awarded-us-patent-for-proprietary-primer-switch-mutation-detection-and
https://www.nasdaq.com/press-release/biocept-announces-agreement-with-healthcare-group-to-provide-covid-19-testing-to
https://www.nasdaq.com/press-release/biocept-reports-second-quarter-2020-financial-results-2020-08-12
https://www.nasdaq.com/press-release/biocept-announces-agreement-with-aegea-biotechnologies-to-develop-new-highly
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/biocept-to-release-second-quarter-2020-financial-results-and-host-investor-conference
https://www.nasdaq.com/press-release/biocept-reaches-covid-19-testing-milestone-with-more-than-7000-specimens-received-and
https://www.nasdaq.com/press-release/leading-independent-proxy-advisory-firms-iss-and-glass-lewis-both-support-biocept
https://www.nasdaq.com/press-release/biocept-awarded-canadian-patent-covering-the-enhanced-detection-of-rare-cells
https://www.nasdaq.com/press-release/biocept-enters-into-agreement-with-reference-based-pricing-network-medical-cost
https://www.nasdaq.com/press-release/biocept-announces-the-availability-of-10000-specimen-collection-kits-for-rt-pcr-covid
https://www.nasdaq.com/press-release/biocept-to-relocate-corporate-offices-and-clia-certified-laboratory-to-new-san-diego
https://www.nasdaq.com/press-release/data-affirming-biocepts-target-selectortm-platform-identifies-cancer-mutations-in
https://www.nasdaq.com/press-release/biocept-to-participate-in-maxim-groups-covid-19-virtual-conference-series-on-may-27
https://www.nasdaq.com/press-release/biocept-expands-its-menu-of-molecular-assay-kit-offering-with-release-of-its-target
https://www.nasdaq.com/press-release/biocept-reports-first-quarter-2020-financial-results-2020-05-13
https://www.nasdaq.com/press-release/biocept-to-release-first-quarter-2020-financial-results-and-host-investor-conference
https://www.nasdaq.com/press-release/biocept-announces-ce-ivd-mark-and-availability-of-its-target-selectortm-egfr
https://www.nasdaq.com/press-release/biocept-launches-unique-line-of-molecular-assay-kits-for-detection-of-key-oncogene
https://www.nasdaq.com/press-release/biocept-announces-pricing-of-%2410.3-million-registered-direct-offering-priced-at-the
https://www.nasdaq.com/press-release/biocept-to-begin-covid-19-testing-2020-04-09
https://www.nasdaq.com/press-release/brazil-patent-granted-for-biocepts-target-selectortm-oncogene-mutation-enrichment-and
https://www.nasdaq.com/press-release/australia-patent-issued-for-primer-switch-mutation-detection-and-amplification
https://www.nasdaq.com/press-release/biocept-enters-into-laboratory-services-agreement-with-second-california-based
https://www.nasdaq.com/press-release/biocept-reports-2019-fourth-quarter-and-full-year-financial-results-2020-03-25
https://www.nasdaq.com/press-release/biocept-to-release-2019-fourth-quarter-and-full-year-financial-results-and-host
https://www.nasdaq.com/press-release/newly-published-data-in-journal-of-clinical-pathology-provides-clinical-validation
https://www.nasdaq.com/press-release/biocept-announces-pricing-of-%246.6-million-registered-direct-offering-priced-at-the
https://www.nasdaq.com/press-release/biocept-announces-pricing-of-%249.2-million-registered-direct-offering-priced-at-the
https://www.nasdaq.com/press-release/biocept-appoints-cory-j.-dunn-senior-vice-president-of-commercial-operations-2020-02
https://www.nasdaq.com/press-release/biocept-enters-into-laboratory-services-agreement-with-california-based-independent
https://www.nasdaq.com/press-release/biocept-to-present-at-the-22nd-annual-bio-ceo-investor-conference-2020-02-04
https://www.nasdaq.com/press-release/biocept-announces-validation-and-availability-of-its-liquid-biopsy-platform-for-the
https://www.nasdaq.com/press-release/biocept-announces-validation-and-availability-of-its-liquid-biopsy-platform-for-the-0
https://www.nasdaq.com/press-release/biocept-inc.-awarded-united-states-patent-for-the-use-of-antibodies-in-combination
https://www.nasdaq.com/press-release/biocept-announces-closing-of-%2410.0-million-underwritten-public-offering-2019-12-12
https://www.nasdaq.com/press-release/biocept-announces-pricing-of-%2410.0-million-underwritten-public-offering-2019-12-09
https://www.nasdaq.com/press-release/biocepts-liquid-biopsy-ctc-testing-for-breast-cancer-to-be-featured-in-poster
https://www.nasdaq.com/press-release/biocept-announces-the-launch-of-its-liquid-biopsy-test-to-detect-trk-biomarkers-in
https://www.nasdaq.com/press-release/biocept-reports-third-quarter-2019-financial-results-2019-11-13
https://www.nasdaq.com/press-release/biocept-announces-ce-ivd-marks-and-availability-of-its-cee-surer-blood-collection
https://www.nasdaq.com/press-release/biocept-to-release-third-quarter-2019-financial-results-and-host-investor-conference
https://www.nasdaq.com/press-release/biocepts-target-selectortm-tests-and-kits-to-be-featured-in-six-poster-presentations
https://www.nasdaq.com/press-release/biocepts-target-selectortm-ctdna-platform-demonstrates-single-copy-detection-for-egfr
https://www.nasdaq.com/press-release/biocept-announces-issuance-of-south-korean-patent-covering-its-target-selectortm
https://www.nasdaq.com/press-release/biocept-to-present-at-two-investment-conferences-in-september-2019-09-03
https://www.nasdaq.com/press-release/high-sensitivity-of-biocepts-target-selectortm-platform-using-cee-suretm-blood
https://www.nasdaq.com/press-release/biocept-receives-three-additional-patents-covering-its-antibody-and-microchannel
https://www.nasdaq.com/press-release/biocept-reports-second-quarter-2019-financial-results-2019-08-12
https://www.nasdaq.com/press-release/biocept-to-release-second-quarter-2019-financial-results-and-host-investor-conference
https://www.nasdaq.com/press-release/biocept-announces-laboratory-services-provider-agreement-with-beaconlbsr-2019-07-22
https://www.nasdaq.com/press-release/biocept-announces-commercial-launch-of-target-selectortm-ngs-breast-panel-the
https://www.nasdaq.com/press-release/thinking-about-buying-stock-aurora-cannabis-armata-pharmaceuticals-biocept-jumei
https://www.nasdaq.com/press-release/biocept-awarded-patent-china-its-circulating-tumor-cell-platform-expanding
https://www.nasdaq.com/press-release/biocept-release-first-quarter-2019-financial-results-and-host-investor-conference
